Phase III trials for aclidinium, a "me-too" antimuscarinic, in COPD (ACCLAIM I & II) - PulmCCM
May 202011

Jones et al randomized 1,647 people with moderate to severe COPD for the two trials, to receive either aclidinium inhaled (a potential tiotropium competitor) once daily or placebo for 1 year. Aclidinium improved FEV1 by ~65 mL. An absolute ~8% more people taking the drug achieved a 4-point SGRQ improvement over those taking placebo. Time to exacerbation was reduced slightly compared to placebo in one of the trials (the overall exacerbation rate was low). There were no serious adverse events. (n=1,647) Respiratory Research 2011;12:55. FREE FULL TEXT

Liked this post? Get a weekly email update (no spam, ever), and explore our library of clinical guidelines, practice updatesreview articles. and board review questions.

PulmCCM is an independent publication, not affiliated with or endorsed by any other organization, society or journal referenced on the website.

Authors: contribute your work to PulmCCM Journal or in a guest blog post.

Leave a Comment